Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Multiple Myeloma
Interventions
DRUG

Bortezomib (Velcade)

"Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 4, 8, and 11 q. 21 days times three cycles.~Patients will undergo three 21-day cycles."

Trial Locations (1)

84112

University of Utah, Salt Lake City

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

University of Arkansas

OTHER